Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

DAIVOBET OINTMENT [SIN12241P]

Active ingredients: BETAMETHASONE DIPROPIONATE 0.643 MG/G EQV BETAMETHASONE | CALCIPOTRIOL MONOHYDRATE 52.2 MCG/G EQV CALCIPOTRIOL

View product's general information
Last updated on 9 October 2026

Product Info

DAIVOBET OINTMENT

[SIN12241P]

Product information

Active Ingredient and Strength

BETAMETHASONE DIPROPIONATE 0.643 MG/G EQV BETAMETHASONE - 0.5 MG/G
CALCIPOTRIOL MONOHYDRATE 52.2 MCG/G EQV CALCIPOTRIOL - 50 MCG/G

Dosage Form

OINTMENT

Manufacturer and Country

LEO LABORATORIES LIMITED - IRELAND

Registration Number

SIN12241P

Licence Holder

DKSH SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

D05AX52

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

Indications
Initial topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy.

Dosing

Posology and method of administration
Posology
Daivobet® Ointment should be applied to the affected area once daily. The recommended treatment period is 4 weeks. There is experience with repeated courses of Daivobet® Ointment up to 52 weeks. If it is necessary to continue or restart treatment after 4 weeks, treatment should be continued after medical review and under regular medical supervision.

When using calcipotriol containing medicinal products, the maximum daily dose should not exceed 15 g, the maximum weekly dose should not exceed 100 g, and the body surface area treated with calcipotriol containing medicinal products should not exceed 30%.

Special Populations
Renal and hepatic impairment
The safety and efficacy of Daivobet® Ointment in patients with severe renal insufficiency or severe hepatic disorders have not been evaluated.

Paediatric population
The safety and efficacy of Daivobet® Ointment in children below 18 years have not been established. Currently available data in children aged 12 to 17 years are described in sections "Undesirable effects and Pharmacodynamics properties" – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information, but no recommendation on a posology can be made.

Method of Administration
Daivobet® Ointment should be applied to the affected area. In order to achieve optimal effect, it is not recommended to take a shower or bath immediately after application of Daivobet® Ointment.

Contraindications

Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Due to the content of calcipotriol, Daivobet® Ointment is contraindicated in patients with known disorders of calcium metabolism.
Due to the content of corticosteroid, Daivobet® Ointment is contraindicated in the following conditions: Viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers, wounds and perianal and genital pruritus.

Daivobet® is contraindicated in erythrodermic, exfoliative and pustular psoriasis.